BioPharma Resources

Drug Trial Radar · NCT07222761

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 915 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

915

Planned (sponsor's estimate)

Start

Jan 2, 2026

Primary completion

May 21, 2029

Study completion Aug 23, 2034

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies. The aim of this study is to see if the safety and efficacy of linvoseltamab alone or in combination with carfilzomib can deliver better outcomes (deeper and longer responses that help extend life) than standard treatment options. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Relapsed and/or Refractory Multiple Myeloma (RRMM)

Interventions

  • LinvoseltamabDrug

    Administered per the protocol

  • CarfilzomibDrug

    Administered per the protocol

  • DaratumumabDrug

    Administered per the protocol

  • DexamethasoneDrug

    Administered per the protocol

  • PomalidomideDrug

    Administered per the protocol

  • BortezomibDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 5 years
  2. Severity of TEAEsTime frame: Up to 5 years
  3. Occurrence of Adverse Events of Special Interest (AESI)Time frame: Up to 5 years
  4. Severity of AESIsTime frame: Up to 5 years
  5. Occurrence of Serious Adverse Events (SAEs)Time frame: Up to 5 years
  6. Severity of SAEsTime frame: Up to 5 years
  7. Minimal Residual Disease (MRD)-negative Complete Response (CR)Time frame: At 12 months
  8. Progression-Free Survival (PFS) per IMWG response criteria as determined by BIRCTime frame: Up to 5 years

Locations

60 sites in 9 countries. Site status is shown where the registry gives one.

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Trinity Health St. Joseph Ann Arbor Hospital

    Ann Arbor, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Stony Brook University Hospital

    Stony Brook, New York · Recruiting

  • OhioHealth

    Columbus, Ohio · Recruiting

  • Baylor University Medical Center

    Dallas, Texas · Recruiting

  • University of Texas Health Science Center, Houston

    Houston, Texas · Recruiting

  • Royal Adelaide Hospital

    Adelaide, Australia · Recruiting

  • Pindara Private Hospital

    Benowa, Queensland, Australia · Recruiting

  • Mater Misericordiae Ltd

    Brisbane, Queensland, Australia · Recruiting

  • Gold Coast Hospital and Health Service

    Southport, Queensland, Australia · Recruiting

  • Epworth Freemasons

    East Melbourne, Victoria, Australia · Recruiting

  • Austin Hospital

    Heidelberg, Victoria, Australia · Recruiting

  • Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Royal Perth Hospital

    Perth, Western Australia, Australia · Recruiting

  • AC Camargo Cancer Center

    São Paulo, Brazil · Recruiting

  • Clinica Medica Sao Germano

    São Paulo, Brazil · Recruiting

  • Cetus Oncologia

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil · Recruiting

  • Oncomed Clinica Oncologica

    Niterói, Rio de Janeiro, Brazil · Recruiting

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Centro Gaucho Integrado, Hospital Mae de Deus

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Centro de Hematologia e Oncologia

    Joinville, Santa Catarina, Brazil · Recruiting

  • ANIMI

    Lages, Santa Catarina, Brazil · Recruiting

  • Unidade de Pesquisa Clinica (UPC); Hospital das Clinicas de Ribeirao Preto da Universidade de Sao Paulo

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Hospital Clinico Universidad de Los Andes

    Santiago, Las Condes, Chile · Recruiting

  • Clinica Alemana de Santiago

    Santiago, Santiago Metropolitan, Chile · Recruiting

  • Clinica UC San Carlos de Apoquindo

    Santiago, Santiago Metropolitan, Chile · Recruiting

  • OncoPrecision

    Santiago, Santiago Metropolitan, Chile · Recruiting

  • Centro de Investigaciones Clinicas Vina del Mar

    Viña del Mar, Valparaiso, Chile · Recruiting

  • Japanese Red Cross Fukuoka Hospital

    Fukuoka, Japan · Recruiting

  • Gunma University Hospital

    Maebashi, Gunma, Japan · Recruiting

  • Tokushima Prefectural Central Hospital

    Tokushima, Tokushima, Japan · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital; Division of Hematology

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul St. Mary's Hospital, The Catholic University of Korea

    Seoul, South Korea · Recruiting

  • Ulsan University Hospital

    Ulsan, South Korea · Recruiting

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeollanam-do, South Korea · Recruiting

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.